NCT02877550View on ClinicalTrials.gov

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 15, 2017

Primary Completion Date

April 28, 2020

Study Completion Date

May 4, 2022

Conditions
Follicular Lymphoma
Interventions
DRUG

Obinutuzumab

Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6

DRUG

Venetoclax

p.o. once daily according to dose level (DL) or MTD

Trial Locations (6)

4031

Universitaetsspital Basel, Basel

6500

Istituto Oncologico della Svizzera Italiana, Bellinzona

7000

Kantonsspital Graubünden, Chur

CH-3010

Inselspital, Bern, Bern

CH-1211

Hopital Cantonal Universitaire de Geneve, Geneva

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT02877550 - Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients | Biotech Hunter | Biotech Hunter